Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA approval for an oral GLP-1 pill for weight management.

MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from the Wegovy injection.

With a new year comes a new set of resolutions and options in the weight loss game. Injectable GLP-1 drugs like Wegovy, Ozempic and Zepbound have helped many people across the world lose weight and keep it off.

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.

Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments that have reshaped the obesity

Federal health officials have released new dietary guidelines aimed at encouraging Americans to avoid processed foods and added sugar. Meanwhile, the FDA has approved the first-ever weight

In December, the FDA approved the once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. Manufacturing of the pill has already started at Novo Nordisk’s facilities in North Carolina.

Med Population Health, the leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the newly FDA-approved Wegovy® pill,